A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

San Bernardino Urological Associates Medical Group Inc

Status and phase: Completed; Phase 4

Conditions: Cancer of Prostate

Treatments: Drug: leuprolide acetate

Study type: Interventional

Funder types: Other

Identifiers

NCT00220194

SBU001

Sanofi Aventis

Details and patient eligibility

About

Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patient with Advanced Ca, on stable dose of Lupron or Zoladex

Exclusion Criteria:

• Previous exposure to Eligard.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)